{"url_path":"/sec/dh/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1861795/0001193125-26-259530-index.html","accession_number":"0001193125-26-259530","cik":"0001861795","ticker":"DH","issuer_name":"Definitive Healthcare Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1861795/0001193125-26-259530-index.html","primary_entity_key":"0001861795","primary_entity_name":"Definitive Healthcare Corp."},"word_count":515,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 4, 2026, Definitive Healthcare Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business on April 13, 2026, the record date for determination of stockholders entitled to vote at the Annual Meeting, there were 105,456,979 shares of Class A common stock and 38,225,333 shares of Class B common stock of the Company issued and outstanding. At the Annual Meeting, the stockholders of the Company (i) elected each of the Company’s nominees for Class II directors, each to serve a three-year term expiring at the 2029 annual meeting of stockholders and until such director’s successor is duly elected and qualified, or until such director’s earlier death, resignation or removal; (ii) ratified the selection of Deloitte & Touche LLP as the Company’s independent auditor for fiscal year 2026; (iii) approved an amendment to the Definitive Healthcare Corp. 2021 Equity Incentive Plan (the “2021 Plan”), to increase the number of shares of Class A common stock, par value $0.001 per share (“Common Stock”) that we will have authority to grant under the 2021 Plan by 15,000,000 from 30,972,789 to 45,972,789; and (iv) approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. A more complete description of each proposal is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026 (the “Proxy Statement”). The final results are set forth below.\n\nProposal 1 – Election of Directors\n\nThe stockholders elected each of the three nominees named below as Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of such vote were:\n\nDirector Nominee\n\n \n\nFor\n\n \n\n \n\nWithheld\n\n \n\n \n\nBroker Non-Votes\n\n \n\nChris Egan\n\n \n\n \n\n115,632,170\n\n \n\n \n\n \n\n5,879,043\n\n \n\n \n\n \n\n10,023,267\n\n \n\nSastry Chilukuri\n\n \n\n \n\n114,385,076\n\n \n\n \n\n \n\n7,126,137\n\n \n\n \n\n \n\n10,023,267\n\n \n\nSamuel A. Hamood\n\n \n\n \n\n118,977,114\n\n \n\n \n\n \n\n2,534,099\n\n \n\n \n\n \n\n10,023,267\n\n \n\nProposal 2 – Ratification of Selection of Independent Public Registered Accounting Firm\n\nThe stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of such vote were:\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\n130,745,809\n\n \n\n \n\n \n\n726,699\n\n \n\n \n\n \n\n61,972\n\n \n\nProposal 3 – Share Increase Proposal\n\nThe stockholders approved an amendment to the 2021 Plan, to increase the number of shares of Common Stock that we will have authority to grant under the 2021 Plan by 15,000,000 from 30,972,789 to 45,972,789. The results of such vote were:\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non-Votes\n\n \n\n \n\n105,140,642\n\n \n\n \n\n \n\n16,351,580\n\n \n\n \n\n \n\n18,991\n\n \n\n \n\n \n\n10,023,267\n\n \n\nProposal 4 – Advisory Vote on Executive Compensation\n\nThe stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The results of such vote were:\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non-Votes\n\n \n\n \n\n108,811,271\n\n \n\n \n\n \n\n12,680,719\n\n \n\n \n\n \n\n19,223\n\n \n\n \n\n \n\n10,023,267\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nDEFINITIVE HEALTHCARE CORP.\n\n \n\n \n\n \n\nDate: June 5, 2026\n\nBy:\n\n/s/ Jonathan Paris\n\n \n\nName:\n\nJonathan Paris\n\n \n\nTitle:\n\nChief Legal Officer"}